Simultaneous Determination of Alogliptin and Pioglitazone in Human Plasma by a Novel LC-MS/MS Method

Author(s): Duddukuru Sri Sesha Sai Praveen, Syed Asha*, Ravi Kumar Pigili

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: A combination of alogliptin and pioglitazone is well tolerated. It does not increase the risk of hypoglycemia. In order to study the bioavailability of aloglipitn in the presence of pioglitazone, it is essential to have a method that can simultaneously detect both in human plasma. A protein precipitation-based method was used to determine alogliptin and pioglitazone simultaneously in human plasma. Protein precipitation causes ion suppression or enhancement in detection methods when compared to other methods.

Objective: To simultaneously quantify alogliptin and pioglitazone in human plasma by LC-MS/MS based method.

Methods: LC-MS/MS method for the simultaneous determination of pioglitazone and alogliptin in human plasma using stable isotope labelled compounds internal standards. The simple and one step solid phase extraction (SPE) was employed to extract the analytes from plasma. The extracted samples were separated on a C18 column by using a 25:75 (v/v) mixture of acetonitrile and 5 mM ammonium formate as the mobile phase at a flow rate of 0.5 mL/min.

Results: The calibration curves obtained were linear (r2= 0.99) over the concentration range of 12.0- 2438.0 ng/mL for pioglitazone and 1.0-202.0 ng/mL for alogliptin. The results of the intra- and interday precision and accuracy studies were found to be within the acceptable limits. The analytes were stable under different stability conditions. All the validation results were found to be within the acceptable limits. The total analytical run time was 3.0 min. There was no interference from plasma matrices.

Conclusion: The developed method is precise and adequately sensitive for detection and quantification of analytes. Thus, the method can be useful for bioavailability and bioequivalence (BA/BE) studies and routine therapeutic drug monitoring with the desired precision and accuracy.

Keywords: Pioglitazone, alogliptin, human plasma, solid-phase extraction, LC-MS/MS, HPLC.

[1]
Kletzien, R.F.; Foellmi, L.A.; Harris, P.K.; Wyse, B.M.; Clarke, S.D. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol. Pharmacol., 1992, 42(4), 558-562.
[PMID: 1435736]
[2]
Hofmann, C.A.; Edwards, C.W., III; Hillman, R.M.; Colca, J.R. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology, 1992, 130(2), 735-740.
[PMID: 1733721]
[3]
Zhang, H.Y.; Reddy, S.R.; Kotchen, T.A. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension, 1994, 24(1), 106-110.
[http://dx.doi.org/10.1161/01.HYP.24.1.106] [PMID: 8020998]
[4]
Chilcott, J.; Tappenden, P.; Jones, M.L.; Wight, J.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin. Ther., 2001, 23(11), 1792-1823.
[http://dx.doi.org/10.1016/S0149-2918(00)80078-8] [PMID: 11768834]
[5]
Kay, S.; Strickson, A.; Puelles, J.; Selby, R.; Benson, E.; Tolley, K. Comparative effectiveness of adding alogliptin to metformin plus sulfonylurea with other DPP-4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis. Diabetes Ther., 2017, 8(2), 251-273.
[http://dx.doi.org/10.1007/s13300-017-0245-8] [PMID: 28275958]
[6]
Abdel-Ghany, M.F.; Ayad, M.F.; Tadros, M.M. Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2017, 1058, 93-101.
[http://dx.doi.org/10.1016/j.jchromb.2017.04.043] [PMID: 28528664]
[7]
US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine: Rockville, MD. 2001.
[8]
Guideline on bioanalytical method validation, Science and Medicinal Health, European Medicines Agency (EMEA). EMEA/CHMP/EWP/192217/2009, 2011.
[9]
Scheen, A.J. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opin. Drug Metab. Toxicol., 2015, 11(6), 1005-1020.
[http://dx.doi.org/10.1517/17425255.2015.1041499] [PMID: 25936384]
[10]
Sripalakit, P.; Neamhom, P.; Saraphanchotiwitthaya, A. High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2006, 843, 164-169.
[PMID: 16815107]
[11]
Arayne, M.S.; Sultana, N.; Mirza, A.Z. Simultaneous determination of gliquidone, pioglitazone hydrochloride, and verapamil in formulation and human serum by RP-HPLC. J. Chromatogr. Sci., 2011, 49(2), 114-117.
[http://dx.doi.org/10.1093/chrsci/49.2.114] [PMID: 21223635]
[12]
Supriya, P.; Madhavi Latha, N.; Rohith, K.B.V.; Ramana, G.V.; Harini, U.; Pawar, A.K.M. Development and validation of UV spectrophotometric and reversed phase-high performance liquid chromatography – PDA methods for the estimation of alogliptin benzoate. Asian J. Pharm. Clin.Res, 2016, 9, 264-269.
[13]
Yadav, P.J.; Kadam, V.N.; Mohite, S.K. Development and validation of UV spectrophotometric method for alogliptin benzoate in bulk drug and tablet formulation. J. Curr. Pharm. Res., 2014, 4, 1286-1290.
[http://dx.doi.org/10.33786/JCPR.2014.v04i04.004]
[14]
Deng, J.; Guo, J.; Dai, R.; Zhang, G.; Xie, H. Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC-MS/MS and its application in a pharmacokinetics study. J. Pharm. Biomed. Anal., 2016, 117, 99-103.
[http://dx.doi.org/10.1016/j.jpba.2015.08.033] [PMID: 26344384]
[15]
Chen, H.; Xia, X.; Li, L.; Jiang, W.; Wang, Y.; Xia, H.; Wang, Z.; Wang, Y. pharmacokinetic and bioavailability study of alogliptin in rat plasma by UPLC-MS/MS. Lat. Am. J. Pharm., 2016, 35, 233-238.
[16]
Ashutosh, K.S.; Manidipa, D.; Seshagiri, R.J.V.L.N.; Gowri, S.J. New validated stability indicating rp-hplc method for simultaneous estimation of metformin and alogliptin in human plasma. J. Chromatogr. Sep. Tech., 2015, 6, 1-6.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 5
Year: 2020
Published on: 15 June, 2020
Page: [564 - 577]
Pages: 14
DOI: 10.2174/1573412915666190314143424
Price: $65

Article Metrics

PDF: 16
HTML: 1